BG107829A - Производни на фумаровата киселина като nf - капа в инхибитор - Google Patents

Производни на фумаровата киселина като nf - капа в инхибитор Download PDF

Info

Publication number: BG107829A
Authority: BG; Bulgaria
Prior art keywords: fumarate; fumaric acid; use according; methyl; ethyl
Prior art date: 2001-01-12

Application number

BG107829A

Other languages

Bulgarian (bg)

English (en)

Inventor

Rajendra Joshi

Hans-Peter Strebel

Peter Petzelbauer

Original Assignee

Fumapharm Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-12

Filing date

2003-05-20

Publication date

2004-12-30

2003-05-20 Application filed by Fumapharm Ag filed Critical Fumapharm Ag

2004-12-30 Publication of BG107829A publication Critical patent/BG107829A/bg

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Neurology (AREA)
Toxicology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)

BG107829A 2001-01-12 2003-05-20 Производни на фумаровата киселина като nf - капа в инхибитор BG107829A (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10101307A DE10101307A1 (de)	2001-01-12	2001-01-12	Fumarsäurederivate als NF-kappaB-Inhibitor

Publications (1)

Publication Number	Publication Date
BG107829A true BG107829A (bg)	2004-12-30

Family

ID=7670424

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107829A BG107829A (bg)	2001-01-12	2003-05-20	Производни на фумаровата киселина като nf - капа в инхибитор

Country Status (22)

Country	Link
US (2)	US20040054001A1 (fr)
EP (1)	EP1408947A2 (fr)
JP (2)	JP2004528281A (fr)
CN (1)	CN1520291A (fr)
AU (1)	AU2002244638B2 (fr)
BG (1)	BG107829A (fr)
BR (1)	BR0206381A (fr)
CA (1)	CA2428075A1 (fr)
CZ (1)	CZ20031918A3 (fr)
DE (1)	DE10101307A1 (fr)
EE (1)	EE200300281A (fr)
HU (1)	HUP0302650A3 (fr)
IL (1)	IL156849A0 (fr)
MX (1)	MXPA03006248A (fr)
NO (1)	NO20031450L (fr)
NZ (1)	NZ525148A (fr)
PL (1)	PL363603A1 (fr)
RU (1)	RU2282440C2 (fr)
SK (1)	SK8252003A3 (fr)
WO (2)	WO2002055066A1 (fr)
YU (1)	YU55903A (fr)
ZA (1)	ZA200305343B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19853487A1 (de) *	1998-11-19	2000-05-25	Fumapharm Ag Muri	Verwendung von Dialkylfumaraten
DE10217314A1 (de)	2002-04-18	2003-11-13	Fumapharm Ag Muri	Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
DE10360869A1 (de) *	2003-09-09	2005-04-07	Fumapharm Ag	Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
BRPI0410805A (pt)	2003-09-09	2006-06-27	Fumapharm Ag	uso de derivados do ácido fumárico para tratamento da insuficiência cardìaca e asma
DE10342423A1 (de) *	2003-09-13	2005-04-14	Heidland, August, Prof. Dr.med. Dr.h.c.	Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden
PL2801354T3 (pl) *	2004-10-08	2017-08-31	Forward Pharma A/S	Kompozycje farmaceutyczne o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego
US20070142905A1 (en) *	2005-12-16	2007-06-21	Medtronic Vascular, Inc.	Medical devices to treat or inhibit restenosis
RU2313337C1 (ru) *	2006-05-18	2007-12-27	Государственное учреждение Научный центр медицинской экологии Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук	Лекарственное средство для лечения хронического гепатита в
EP2101772B1 (fr) *	2006-12-06	2012-04-25	Cornell Research Foundation, Inc.	Agents de blocage neuromusculaire à durée intermédiaire, et leurs antagonistes
EP2139467B1 (fr) *	2007-02-08	2016-09-21	Biogen MA Inc.	Neuroprotection dans des maladies démyélinisantes
DK2653873T3 (da)	2007-02-08	2022-07-25	Biogen Ma Inc	Sammensætninger og anvendelser til behandling af multipel sklerose
KR20090028047A (ko) *	2007-09-13	2009-03-18	경북대학교 산학협력단	디메틸푸마레이트의 신규 용도
DE102008030023A1 (de) *	2008-06-16	2009-12-17	Eberhard-Karls-Universität Tübingen Universitätsklinikum	Arzneimittel zur Behandlung einer durch Parasiten verursachten Krankheit
ES2477884T3 (es)	2008-08-19	2014-07-18	Xenoport, Inc.	Profármacos de hidrogenofumarato de metilo, composiciones farmacéuticas de los mismos y procedimientos de uso
RU2743637C2 (ru)	2009-01-09	2021-02-20	Фвп Ип Апс	Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице
WO2010107488A1 (fr)	2009-03-17	2010-09-23	Cornell University	Agents de blocage neuromusculaires non dépolarisants réversibles et leur méthode
EP3318249A1 (fr) *	2009-04-29	2018-05-09	Biogen MA Inc.	Régimes posoloqiques du fumarate de diméthyle pour le traitement de la sclérose en plaques
US9220700B2 (en)	2009-08-19	2015-12-29	Cornell University	Cysteine for physiological injection
PH12013502498A1 (en)	2011-06-08	2014-01-20	Biogen Ma Inc	Process for preparing high purity and crystalline dimethyl fumarate
US9504679B2 (en)	2011-12-19	2016-11-29	Bjoern Colin Kahrs	Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en)	2011-12-19	2013-06-20	Ares Trading S.A.	Pharmaceutical compositions
KR20140129136A (ko)	2012-02-07	2014-11-06	제노포트 인코포레이티드	모르폴리노알킬 푸마레이트 화합물, 약제학적 조성물 및 사용 방법
WO2014031844A1 (fr) *	2012-08-22	2014-02-27	Xenoport, Inc.	Méthodes d'administration du monométhyl fumarate et des promédicaments associés présentant des effets secondaires réduits
WO2014031892A1 (fr)	2012-08-22	2014-02-27	Xenoport, Inc.	Formes pharmaceutiques orales de fumarate de méthyle-hydrogène et leurs promédicaments
US20140171504A1 (en)	2012-12-14	2014-06-19	Georgia Regents Research Institute, Inc.	Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
CN105142628A (zh)	2012-12-21	2015-12-09	比奥根玛公司	氘取代的富马酸盐衍生物
KR101379427B1 (ko) *	2013-02-13	2014-03-28	경북대학교병원	디메틸푸마레이트를 유효성분으로 포함하는 신섬유증의 예방 또는 치료용 조성물
EP3366668B1 (fr)	2013-03-14	2023-06-21	Alkermes Pharma Ireland Limited	Promédicaments de fumarates et leur utilisation pour le traitement de diverses maladies
US8669281B1 (en)	2013-03-14	2014-03-11	Alkermes Pharma Ireland Limited	Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en)	2013-03-24	2019-01-15	Arbor Pharmaceuticals, Llc	Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en)	2013-06-07	2016-04-05	Xenoport, Inc.	Method of making monomethyl fumarate
US9421182B2 (en)	2013-06-21	2016-08-23	Xenoport, Inc.	Cocrystals of dimethyl fumarate
TW201516020A (zh)	2013-09-06	2015-05-01	Xenoport Inc	（ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途
CN104434904B (zh) *	2013-09-22	2018-09-04	深圳翰宇药业股份有限公司	一种复方微丸胶囊的制备方法及其制备的复方微丸胶囊
SG10201913076PA (en) *	2013-12-12	2020-02-27	Almirall Sa	Pharmaceutical compositions comprising dimethyl fumarate
EP3079663A1 (fr) *	2013-12-13	2016-10-19	Biogen MA Inc.	Forme pharmaceutique à libération contrôlée pour administration une fois par jour de fumarate de diméthyle
TWI572358B (zh)	2013-12-20	2017-03-01	財團法人生物技術開發中心	α－烯醇化酶特異性抗體及其使用在免疫疾病之方法
CA2940845C (fr)	2014-02-24	2019-09-24	Alkermes Pharma Ireland Limited	Sulfonamide et promedicaments de fumarates de sulfinamide et leur utilisation dans le traitement de diverses maladies
US9326947B1 (en)	2014-02-28	2016-05-03	Banner Life Sciences Llc	Controlled release fumarate esters
EP3501510B1 (fr)	2014-02-28	2020-07-01	Banner Life Sciences LLC	Capsules entériques molles à libération contrôlée d'esters de fumarate
US10098863B2 (en)	2014-02-28	2018-10-16	Banner Life Sciences Llc	Fumarate esters
US9636318B2 (en)	2015-08-31	2017-05-02	Banner Life Sciences Llc	Fumarate ester dosage forms
WO2015128492A1 (fr) *	2014-02-28	2015-09-03	Maghazachi Azzam A	Monométhylfuramate et diméthylfumarate pour l'activation de cellules tueuses naturelles
US9999672B2 (en)	2014-03-24	2018-06-19	Xenoport, Inc.	Pharmaceutical compositions of fumaric acid esters
CN104027311A (zh) *	2014-05-09	2014-09-10	万特制药(海南)有限公司	一种含有富马酸二甲酯的肠溶缓释微丸
WO2016061393A1 (fr)	2014-10-15	2016-04-21	Xenoport, Inc.	Composés de fumarate, compositions pharmaceutiques et procédés d'utilisation
WO2016074684A1 (fr) *	2014-11-11	2016-05-19	Syddansk Universitet	Dérivés d'acide fumarique à usage médical
MA40982A (fr) *	2014-11-19	2017-09-26	Biogen Ma Inc	Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
CN104523602B (zh) *	2014-12-12	2018-06-05	广东东阳光药业有限公司	一种富马酸二甲酯肠溶微片及其制备方法
CN105797154B (zh) *	2014-12-31	2020-03-10	中国科学院上海生命科学研究院	软骨干细胞的分离及其应用
EP3270911A4 (fr) *	2015-03-17	2018-08-29	Hetero Labs Limited	Compositions pharmaceutiques de fumarate de diméthyle
EA201890068A1 (ru) *	2015-06-17	2018-09-28	Байоджен Ма Инк.	Частицы диметилфумарата и фармацевтические композиции на их основе
US10213411B2 (en)	2015-08-27	2019-02-26	Vijaykumar Rajasekhar	Use of prodrugs of fumarates in treating heart failure diseases
WO2017060400A1 (fr)	2015-10-07	2017-04-13	Neurovive Pharmaceutical Ab	Métabolites protégés à base d'acide carboxylique pour le traitement des maladies liées à des dysfonctions mitochondriales
DE102015117882A1 (de) *	2015-10-21	2017-04-27	Mehrdad Ghashghaeinia	Pharmazeutische Zusammensetzung
US10463642B2 (en)	2016-02-01	2019-11-05	Vijaykumar Rajasekhar	Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
BR112018016300A2 (pt) *	2016-02-12	2018-12-26	Univ Zuerich	fumarato de dimetila (dmf) para prevenção ou tratamento de gota, acne, diabetes, vitiligo e/ou pioderma gangrenoso
CN106265621B (zh) *	2016-09-19	2019-05-17	苏州大学	富马酸二甲酯在制备预防和治疗移植物抗宿主病及移植物抗白血病药物中的应用
JP6866603B2 (ja) *	2016-10-12	2021-04-28	三菱ケミカル株式会社	樹脂組成物、防汚塗料組成物および樹脂組成物の製造方法
CN107088190A (zh) *	2016-11-23	2017-08-25	中南大学湘雅医院	富马酸酯在制备治疗肝病药物中的应用
CN110590919B (zh) *	2017-05-24	2022-05-24	中国海洋大学	含鸟氨酸的短肽及其应用
KR20200018458A (ko)	2017-06-23	2020-02-19	알미랄, 에스.에이.	디메틸 푸마레이트를 포함하는 약학 조성물
WO2020094767A1 (fr)	2018-11-08	2020-05-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Utilisation d'activateurs de nrf2 pour le traitement d'infections à staphylocoque doré
CA3175830A1 (fr)	2019-04-17	2020-10-22	Sundeep Dugar	Promedicaments a base de monomethylfumarate
US11903918B2 (en)	2020-01-10	2024-02-20	Banner Life Sciences Llc	Fumarate ester dosage forms with enhanced gastrointestinal tolerability
EP4200275A2 (fr) *	2020-08-21	2023-06-28	Sitryx Therapeutics Limited	Nouveaux composés
EP4580612A1 (fr)	2022-09-02	2025-07-09	Institut National de la Santé et de la Recherche Médicale	Utilisation d'activateurs de nrf2 pour le traitement de la maladie des petits vaisseaux cérébraux

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2993837A (en) *	1959-07-13	1961-07-25	Frosst & Co Charles E	Enteric coated tablets
FR6808M (fr) *	1967-09-22	1969-03-24
US3832287A (en) *	1972-03-02	1974-08-27	Lilly Co Eli	Dipeptide antibiotic and method for the production thereof
DE3127432A1 (de) *	1981-07-11	1983-02-03	Bayer Ag, 5090 Leverkusen	Verfahren zur herstellung von fumarsaeuremonoester
US5149695A (en) *	1985-01-15	1992-09-22	Speiser Peter P	Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
CH664150A5 (de) *	1985-01-15	1988-02-15	Peter Paul Prof Dr Speiser	Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
JPS61194020A (ja) *	1985-02-22	1986-08-28	Dai Ichi Seiyaku Co Ltd	網膜症治療剤
US5242905A (en) *	1987-09-04	1993-09-07	Dexter Chemical Corporation	Pharmaceutical compositions for the treatment of psoriasis
US5214196A (en) *	1987-09-04	1993-05-25	Dexter Chemical Corporation	Diethyl ester of di-glycyl fumaramide
US4959389A (en) *	1987-10-19	1990-09-25	Speiser Peter P	Pharmaceutical preparation for the treatment of psoriatic arthritis
US5424332A (en) *	1987-10-19	1995-06-13	Speiser; Peter P.	Pharmaceutical composition and process for the production thereof
WO1992012952A1 (fr) *	1991-01-18	1992-08-06	Dexter Chemical Corporation	Derives d'acide malique et compositions pour le traitement du psoriasis
IT1251166B (it) *	1991-08-09	1995-05-04	Chiesi Farma Spa	Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
US5763408A (en) *	1992-06-03	1998-06-09	Fuji Photo Film Co., Ltd.	Amino acid derivatives and application thereof
AU7060394A (en) *	1993-06-08	1995-01-03	Raymond K. Brown	Therapeutic compositions and methods of use
US5407772A (en) *	1993-11-30	1995-04-18	Xerox Corporation	Unsaturated polyesters
IL110380A0 (en) *	1994-07-20	1994-10-21	Agis Ind 1983 Ltd	Antiviral topical pharmaceutical compositions
US5589504A (en) *	1994-07-26	1996-12-31	Cornell Research Foundation, Inc.	Treatment of newborn jaundice
WO1998004290A2 (fr) *	1996-07-26	1998-02-05	Perrine Susan P	Compositions contenant un agent inducteur ainsi qu'un agent antiviral et destinees au traitement de troubles cellulaires, sanguins et viraux
TR199901416T2 (xx) *	1996-12-18	1999-08-23	Basf Aktiengesellschaft	Heterosiklik karbonikasit t�revleri.
WO1998027970A2 (fr) *	1996-12-24	1998-07-02	National Research Council Of Canada	Traitement de maladies ou prevention de dommages cellulaires causes par des radicaux libres contenant de l'oxygene
US5972363A (en) *	1997-04-11	1999-10-26	Rohm And Haas Company	Use of an encapsulated bioactive composition
DE19721099C2 (de) *	1997-05-20	1999-12-02	Fumapharm Ag Muri	Verwendung von Fumarsäurederivaten
DE19735410A1 (de) *	1997-08-14	1999-02-18	Basf Ag	2-{3-[4-(2-t-Butyl-6-trifluormethylpyrimidin-4-yl)piperazin-1-yl]propylmercapto}pyrimidin-4-ol-fumarat
DE19814358C2 (de) *	1998-03-31	2002-01-17	Fumapharm Ag Muri	Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) *	1998-08-31	2002-01-17	Fumapharm Ag Muri	Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) *	1998-10-20	2002-01-17	Fumapharm Ag Muri	Fumarsäure-Mikrotabletten
DE19853487A1 (de) *	1998-11-19	2000-05-25	Fumapharm Ag Muri	Verwendung von Dialkylfumaraten
DE10000577A1 (de) *	2000-01-10	2001-07-26	Fumapharm Ag Muri	Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
RU2160589C1 (ru) *	2000-05-18	2000-12-20	Алекс Кашлинский	Средство для снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома и способ снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома с использованием этого средства

2001
- 2001-01-12 DE DE10101307A patent/DE10101307A1/de not_active Withdrawn
- 2001-04-19 WO PCT/EP2001/004454 patent/WO2002055066A1/fr not_active Ceased
2002
- 2002-01-08 BR BR0206381-6A patent/BR0206381A/pt not_active IP Right Cessation
- 2002-01-08 HU HU0302650A patent/HUP0302650A3/hu unknown
- 2002-01-08 PL PL02363603A patent/PL363603A1/xx not_active Application Discontinuation
- 2002-01-08 NZ NZ525148A patent/NZ525148A/en unknown
- 2002-01-08 IL IL15684902A patent/IL156849A0/xx unknown
- 2002-01-08 CA CA002428075A patent/CA2428075A1/fr not_active Abandoned
- 2002-01-08 EP EP02712806A patent/EP1408947A2/fr not_active Withdrawn
- 2002-01-08 YU YU55903A patent/YU55903A/sh unknown
- 2002-01-08 WO PCT/EP2002/000108 patent/WO2002055067A2/fr not_active Ceased
- 2002-01-08 CN CNA02803628XA patent/CN1520291A/zh active Pending
- 2002-01-08 RU RU2003124751/15A patent/RU2282440C2/ru active
- 2002-01-08 SK SK825-2003A patent/SK8252003A3/sk not_active Application Discontinuation
- 2002-01-08 MX MXPA03006248A patent/MXPA03006248A/es not_active Application Discontinuation
- 2002-01-08 AU AU2002244638A patent/AU2002244638B2/en not_active Ceased
- 2002-01-08 CZ CZ20031918A patent/CZ20031918A3/cs unknown
- 2002-01-08 JP JP2002555801A patent/JP2004528281A/ja not_active Withdrawn
- 2002-01-08 US US10/250,983 patent/US20040054001A1/en not_active Abandoned
- 2002-01-08 EE EEP200300281A patent/EE200300281A/xx unknown
2003
- 2003-03-28 NO NO20031450A patent/NO20031450L/no not_active Application Discontinuation
- 2003-05-20 BG BG107829A patent/BG107829A/bg unknown
- 2003-07-10 ZA ZA200305343A patent/ZA200305343B/en unknown
2007
- 2007-08-02 US US11/833,150 patent/US20080233185A1/en not_active Abandoned
2008
- 2008-11-13 JP JP2008290821A patent/JP2009073854A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EE200300281A (et)	2003-10-15
SK8252003A3 (en)	2003-12-02
HUP0302650A3 (en)	2009-08-28
US20040054001A1 (en)	2004-03-18
DE10101307A1 (de)	2002-08-01
YU55903A (sh)	2006-08-17
IL156849A0 (en)	2004-02-08
ZA200305343B (en)	2004-08-17
US20080233185A1 (en)	2008-09-25
EP1408947A2 (fr)	2004-04-21
WO2002055067A3 (fr)	2004-02-26
JP2004528281A (ja)	2004-09-16
NO20031450D0 (no)	2003-03-28
RU2003124751A (ru)	2005-01-10
WO2002055066A1 (fr)	2002-07-18
HUP0302650A2 (hu)	2003-11-28
CZ20031918A3 (en)	2004-04-14
JP2009073854A (ja)	2009-04-09
MXPA03006248A (es)	2004-04-02
WO2002055067A2 (fr)	2002-07-18
NZ525148A (en)	2006-06-30
PL363603A1 (en)	2004-11-29
RU2282440C2 (ru)	2006-08-27
CA2428075A1 (fr)	2002-07-18
BR0206381A (pt)	2004-08-03
CN1520291A (zh)	2004-08-11
AU2002244638B2 (en)	2005-05-05
NO20031450L (no)	2003-09-12

Publication	Publication Date	Title
BG107829A (bg)	2004-12-30	Производни на фумаровата киселина като nf - капа в инхибитор
RS55903B1 (sr)	2017-09-29	Obujmica za crevo
RU2313339C2 (ru)	2007-12-27	Применение производных фумаровой кислоты для лечения сердечной недостаточности и астмы
CA2390886C (fr)	2008-08-19	Utilisation de derives d'acide fumarique pour traiter des maladies mitochondriales
RU2459621C2 (ru)	2012-08-27	Применение производных фумаровой кислоты для лечения сердечной недостаточности, инфаркта миокарда и стенокардии
AU746958B2 (en)	2002-05-09	The use of fumaric acid derivatives in transplant medicine
IL132819A (en)	2004-12-15	Use of fumaric acid derivatives in the preparation of medicaments
SK285601B6 (sk)	2007-04-05	Použitie jedného alebo viacerých dialkylfumarátovna výrobu farmaceutického prípravku a farmaceutický prípravok
US6994873B2 (en)	2006-02-07	Multiparticulate formulations of lithium salts for oral administration suitable for once-a-day administration
HK1069309A (en)	2005-05-20	Fumaric acid derivatives as nf-kappab inhibitors
HK1094650B (en)	2011-07-08	The use of fumaric acid derivatives in the manufacture of a medicament for treating asthma and chronic obstructive pulmonary diseases